Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$0.94 and traded as low as C$0.86. Oncolytics Biotech shares last traded at C$0.93, with a volume of 134,300 shares traded.
Analyst Ratings Changes
Separately, Jones Trading lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Read Our Latest Analysis on Oncolytics Biotech
Oncolytics Biotech Stock Performance
The company has a market cap of C$71.68 million, a PE ratio of -2.59 and a beta of 1.35. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The firm's 50-day simple moving average is C$0.70 and its two-hundred day simple moving average is C$0.94.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
